Lyra Therapeutics, Inc. (LYRA)

USD 0.17

(-6.54%)

Market Cap (In USD)

11.13 Million

Revenue (In USD)

1.55 Million

Net Income (In USD)

-62.68 Million

Avg. Volume

1.11 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.163-6.79
PE
-
EPS
-
Beta Value
-0.036
ISIN
US55234L1052
CUSIP
55234L105
CIK
1327273
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Maria Palasis Ph.D.
Employee Count
-
Website
https://lyratherapeutics.com
Ipo Date
2020-05-01
Details
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.